Kidney patients have a higher risk of severe COVID-19 infection - vaccinations reduced the need for hospitalization
A recent study shows that COVID-19 vaccinations reduced morbidity and mortality due to COVID-19 in dialysis and kidney transplant patients compared to unvaccinated patients. Patients who had been vaccinated were at half the risk of becoming hospitalized because of COVID-19 compared to unvaccinated patients. The risk of death decreased significantly with booster vaccines especially in kidney transplant patients. However, the vaccine protection of these patients remained weaker than that of healthy people.

A study led by Professor Patrik Finne and the doctoral dissertation of Bachelor of Medicine Hanna Helanne focused on patients (5,755) in the Finnish Registry for Renal Diseases who were on dialysis or had a kidney transplant. These patients are at greater risk of developing a severe form of COVID-19 compared to healthy people.
The study assessed how the COVID-19 vaccine would prevent hospitalization and mortality in patients receiving renal replacement therapy compared to unvaccinated persons.
Each research subject had 10 control persons of the same age, sex and municipality of residence. During the years of the study 2020–2022, 1,713 kidney patients and 10,702 control persons contracted an infection caused by COVID-19.
Infections in kidney patients more severe and vaccine effectiveness lower
COVID-19 vaccinations significantly reduced the risk of kidney patients becoming hospitalized, but not as effectively as in control persons. More than three booster vaccines reduced the mortality rate of kidney transplant patients by 62% compared to unvaccinated patients.
In patients receiving dialysis treatment, 2–3 vaccine doses reduced the risk of hospitalization by 47 per cent and in kidney transplant patients by 50 per cent. In control persons, COVID-19 vaccines prevented three out of four hospitalizations.
The COVID-19 infections of dialysis patients were more severe than those of the control persons and their vaccine efficacy was lower. However, the vaccines prevented the hospitalization of every other patient. Booster vaccines reduced the risk of death significantly especially in kidney transplant patients.
Kidney patients are in the target group of the autumn booster vaccine.
Keywords
Contacts
Patrik FinneProfessor, HUS Abdominal Center
Tel:+358 50 427 0800patrik.finne@hus.fiHanna HelanneDoctoral Researcher, Bachelor of Medicine, University of Helsinki
hanna.helanne@helsinki.fiAbout HUS
HUS Helsinki University Hospital is the biggest provider of specialized healthcare in Finland. Our high expertise is internationally recognized and accredited. As a university hospital, we are on the cutting edge of developing and evaluating our treatment methods and activities.
HUS treats almost 700,000 patients every year. Our more than 27,000 professionals work to provide the best possible care for our patients. We are responsible for organizing specialized health care in the Uusimaa region. The treatment of many rare and difficult diseases in Finland has been centralized to HUS as well.
HUS – Leading healthcare
The HUS media service is available for the media Mon–Thu 10:00 a.m.–4:00 p.m. and Fri 10:00 a.m.–3:00 p.m., tel. 050 427 2875, or via e-mail: viestinta@hus.fi.
hus.fi/en
Alternative languages
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
Gips räcker vid frakturer på mediala humerusepikondylen vid armbågsleden hos barn9.9.2025 09:55:56 EEST | Pressmeddelande
I en nyligen publicerad studie framgick det att gipsning som behandling vid frakturer på mediala humerusepikondylen hos barn är en lika effektiv behandlingsform som operation. De resultat som man nu fått stöder gipsbehandling som primär behandlingsform och behandlingen kan förenhetligas på riksnivå.
Kipsi riittää lasten kyynärnivelen koukistajalisäkkeen murtumissa9.9.2025 09:55:56 EEST | Tiedote
Juuri julkaistussa tutkimuksessa selvisi, että lasten kyynärnivelen koukistajalisäkkeen murtumien hoidossa kipsaus on yhtä tehokas hoitomuoto kuin leikkaus. Nyt saadut tulokset tukevat kipsihoidon käyttöä ensisijaisena hoitomuotona, ja hoitoa voidaan yhtenäistää kansallisesti.
Den nyaste ekonomiska prognosen för hela 2025: HUS är på väg att uppnå sina ekonomiska mål för 20258.9.2025 12:09:48 EEST | Pressmeddelande
HUS-sammanslutningens styrelse behandlade på sitt möte verksamheten och ekonomin i januari–juli samt den nyaste årsprognosen för hela 2025. HUS-sammanslutningens operativa resultat beräknas uppvisa ett överskott på 0,1 miljoner euro. Sammanslutningens styrelse fastställde också investeringsplanen och investeringsprogrammet för de kommande åren.
Koko vuoden 2025 uusin talousennuste: HUS pääsemässä vuonna 2025 taloudellisiin tavoitteisiinsa8.9.2025 12:09:48 EEST | Tiedote
HUSin yhtymähallitus käsitteli kokouksessaan tammi–heinäkuun taloutta sekä uusinta koko vuoden 2025 vuosiennustetta. HUS-yhtymän operatiivisen tuloksen ennustetaan päätyvän 0,1 miljoonaa euroa ylijäämäiseksi. Yhtymähallitus vahvisti myös tulevien vuosien investointisuunnitelman ja -ohjelman.
Förebyggande av RS-virusinfektion hos spädbarn inleds på HUS sjukhus3.9.2025 14:17:24 EEST | Pressmeddelande
RS-virus (respiratory syncytial virus, RSV) är den vanligaste orsaken till luftvägsinfektioner som kräver sjukhusvård hos små barn. HUS erbjuder en antikropp som utvecklats mot RS-virus, det vill säga nirsevimab åt nyfödda och barn under ett år som hör till riskgrupperna.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom